QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review.

Autor: Khokhar B; Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Lexington, MA. Electronic address: Bilal.Khokhar@takeda.com., Chiang B; Global Patient Safety Evaluation, Takeda Development Center Americas, Inc., Lexington, MA., Iglay K; Real-world Evidence and Patient Outcomes, CERobs Consulting, LLC, Wrightsville Beach, NC., Reynolds K; Real-world Evidence and Patient Outcomes, CERobs Consulting, LLC, Wrightsville Beach, NC; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC., Rodriguez-Ormaza N; Real-world Evidence and Patient Outcomes, CERobs Consulting, LLC, Wrightsville Beach, NC; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC., Spalding W; Global Evidence and Outcomes, Takeda Development Center Americas, Inc., Lexington, MA., Freedland E; Global Patient Safety Evaluation, Takeda Development Center Americas, Inc., Lexington, MA.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2024 Jun; Vol. 25 (4), pp. 285-318. Date of Electronic Publication: 2024 Feb 17.
DOI: 10.1016/j.cllc.2024.02.005
Abstrakt: A systematic literature review was conducted to determine the incidence and mortality of QT-interval prolongation (QTp), torsades de pointes (TdP), and heart failure (HF) in patients with non-small cell lung cancer (NSCLC) who received epidermal growth factor receptor (EGFR) TKIs. Of 296 identified publications, 95 met eligibility criteria and were abstracted for QTp/TdP and HF outcomes (QTp/TdP: 83 publications, including 5 case study publications; HF: 79 publications, including 6 case study publications [involving 8 patients]). QTp incidence ranged from 0% to 27.8% in observational studies and from 0% to 11% in clinical trials, with no deaths due to QTp. There were no TdP events or deaths due to TdP. The incidence of HF ranged from 0% to 8%, and HF mortality rates ranged from 0% to 4%. Patients receiving treatment with EGFR TKIs should be monitored for signs of QTp, TdP, and HF per prescribing information. Standardized definitions and methods to improve monitoring of QTp, TdP, and HF-related events are needed in patients with NSCLC.
Competing Interests: Disclosure B.K. is employed by Takeda. B.C. was employed by Takeda during the time this research was conducted. K.I. consulted on this project through CERobs Consulting, LLC; K.I. reports that Takeda Pharmaceuticals contracted with CERobs Consulting, LLC, a consulting firm with focus on real-world evidence, outcomes research, and epidemiology and clinical outcome assessments, including patient reported outcomes. K.R. consulted on this project through CERobs Consulting, LLC; K.R. reports that Takeda Pharmaceuticals contracted with CERobs Consulting, LLC, a consulting firm with focus on real-world evidence, outcomes research, and epidemiology and clinical outcome assessments, including patient reported outcomes. N.R-O. consulted on this project through CERobs Consulting, LLC; N.R-O. reports that Takeda Pharmaceuticals contracted with CERobs Consulting, LLC, a consulting firm with focus on real-world evidence, outcomes research, and epidemiology and clinical outcome assessments, including patient reported outcomes. W.S. is employed by Takeda. E.F. is employed by Takeda.
(Copyright © 2024 Takeda Development Center Americas, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: